Treating atrial fibrillation with radiofrequency ablation to reverse changes in microRNAs regulating the ion-channel proteins

Bratisl Lek Listy. 2021;122(6):396-404. doi: 10.4149/BLL_2021_066.

Abstract

Objective: To investigate the possible molecular mechanisms of radiofrequency ablation (RFA) for treating atrial fibrillation (AF) and the microRNA (miRNA) target for intervention in the future.

Methods: We examined the changes in miRNAs regulating the atrial ion-channel proteins across the whole genome. We compared findings from 90 AF patients with those from 90 healthy subjects before RFA and three months after RFA.

Result: Twenty-one miRNAs regulating ion-channel proteins were differentially expressed more than ten-fold, and the findings were completely reversed after RFA as compared with the pre-RFA results. The colonial regulating effects of miRNAs regulating the outward K+ current channels such as those for the ultra-rapid delayed rectifier potassium current (Ikur), voltage-dependent delayed rectifier potassium current (Ikr), and delayed rectifier potassium channel current (Iks) were more unanimous and stronger, while this was not the case for miRNAs regulating the L-type Ca2+ current and INa current channels. Generally, miR-1266 levels were increased in the blood but down-regulated in the rheumatic atrial tissue, while a dual luciferase test indicated that SCN5A was the direct target gene of miR-1266.

Conclusion: Using RFA to treat AF may have an impact via reversing the changes in miRNAs regulating the ion-channel proteins, especially for outward K+ current channels such as Ikur, Ikr, and Iks, which may play a major role in electrical remodeling in AF. It may be that miR-1266 is an antiarrhythmic miRNA and an AF intervention target in the future (Tab. 2, Fig. 4, Ref. 46).

Keywords: atrial fibrillation; genomics; miRNA; radiofrequency ablation ion-channel proteins..

MeSH terms

  • Anti-Arrhythmia Agents
  • Atrial Fibrillation* / drug therapy
  • Atrial Fibrillation* / genetics
  • Atrial Fibrillation* / surgery
  • Heart Atria
  • Humans
  • MicroRNAs* / genetics
  • Radiofrequency Ablation*

Substances

  • Anti-Arrhythmia Agents
  • MicroRNAs